Michael C Naill

Title: Michael C. Naill: Innovator in Cancer Treatment

Introduction

Michael C. Naill is a prominent inventor based in Stow, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of multi-specific binding proteins. His work aims to improve therapeutic options for patients suffering from cancer.

Latest Patents

Michael C. Naill holds a patent for "Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen." This patent focuses on methods for treating cancer by utilizing multi-specific binding proteins that target NKG2D, CD16, and tumor-associated antigens such as HER2. The disclosure includes the use of these proteins in combination with corticosteroids to minimize the risk of infusion-related reactions. Additionally, it addresses the treatment of cancers with low or moderate HER2 expression levels. The patent also encompasses pharmaceutical formulations that include these multi-specific binding proteins.

Career Highlights

Michael C. Naill is associated with Dragonfly Therapeutics, Inc., where he continues to advance his research in cancer therapies. His work is characterized by a commitment to developing innovative solutions that can significantly impact patient care.

Collaborations

Michael collaborates with notable colleagues, including Jean-Marie Cuillerot and Mark DeRose. Their combined expertise contributes to the advancement of cancer treatment methodologies.

Conclusion

Michael C. Naill is a dedicated inventor whose work in cancer treatment through multi-specific binding proteins showcases his commitment to improving patient outcomes. His innovative approaches and collaborations highlight the importance of research in the fight against cancer.